SubHero Banner

Nayzilam® (midazolam) – New orphan drug approval

May 20, 2019 - UCB announced the FDA approval of Nayzilam (midazolam), for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

Download PDF